India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’

 
• By Anju Ghangurde

Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.

L to R: Taranpreet Lamba, VP & Head, Portfolio Planning & IP Litigation, Sun Pharma; Sudarshan Jain, Secretary General, IPA India; Robert Stanley, Global Head Intellectual Property & Legal Innovation, Head Legal, International ad interim, Novartis; Leena Menghaney, IP Advisor & Head, MSF, South Asia; Christoph Koenen, Global Head of Clinical Development & Operations, Bayer; & Pravin Anand, Managing Partner, Anand and Anand • Source: BioAsia

More from India

More from Focus On Asia